A randomized, placebo-controlled, crossover trial of danazol for the treatment of premenstrual syndrome
A randomized, placebo-controlled, crossover trial of danazol for the treatment of premenstrual syndrome
复制标题
达那唑治疗经前综合症的随机、安慰剂对照、交叉试验
DOI：
10.1016/0306-4530(94)00053-d
复制
发表时间：
1995
影响因子：
3.7
通讯作者：
R. Reid
中科院分区：
文献类型：
--
作者：
P. Hahn;D. A. Vugt;R. Reid
To investigate whether danazol is more effective than placebo for the treatment of premenstrual syndrome (PMS), we conducted a randomized, double-blind, crossover study comparing three successive cycles of danazol (200 mg bid) to three cycles of placebo. Thirty-one women meeting rigorous criteria for a diagnosis of severe PMS over two pretreatment cycles were enrolled; 28 of these subjects completed at least one cycle of treatment with symptom recordings, which were entered into the analysis. A significant period effect confounded the planned within-subject analysis and therefore, the main treatment comparisons were confined to the first period only. Symptom scores on the Premenstrual Tension Self-Rating Scale (PMTS), Beck Depression Inventory (BDI), and a Visual Analogue Scale (VAS) were compared for the premenstrual week in the last cycle of treatment. For the 16 patients on danazol, scores on the PMTS decreased by an average of 14.0 (10.7) (standard deviation) points from a baseline of 25.4 (5.6) points. For the 12 patients on placebo, PMTS scores decreased by an average of 3.6 (9.5) points from a baseline of 23.5 (5.8) points (14.0 vs. 3.6; p = .0133, unpaired t-test). Seven (43.8%) of the subjects on danazol achieved a clinically relevant reduction of symptoms into the asymptomatic range (PMTS scores ≤5) as compared to one (8.3%) of the subjects on placebo. Thus, danazol (200 mg bid) provided greater relief from severe PMS during the premenstrual week than did placebo.
联合使用促性腺激素释放激素激动剂和雌激素/孕激素成功治疗严重经前综合症。
DOI：
10.1210/jcem-72-2-252
发表时间：
1991
期刊：
The Journal of clinical endocrinology and metabolism
影响因子：
--
作者：
Mortola,JF;Girton,L;Fischer,U
通讯作者：
Fischer,U